Pipeline
Last Updated Date: October 22, 2020
The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.
The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
Clinical Stage Programs1
NDA/BLA/MAA, P3 and Registrational P2 Trials
NMEs via In-Licensing, Options, and Product Acquisitions
Breakthrough Therapy Designations2
1 Including in-licensed or acquired.
2 Expected submission and/or approvals in 2021.
On this page
Viral Diseases
Inflammatory Diseases
Oncology

Viral Diseases
Emerging Virus
-
Remdesivir inhaled form
COVID-19
PHASE 1
HIV
-
Lenacapavir capsid inhibitor (GS-6207)
HIV LA HTE
PHASE 3 Registrational for HTE
-
Lenacapavir capsid inhibitor (GS-6207)
HIV LA virologically suppressed2
PHASE 2
-
bNAb combination (GS-5423, GS-2872)
HIV cure3
PHASE 2
-
LefitolimodTLR-9 agonist
HIV cure3
PHASE 2
-
Vesatolimod TLR-7 agonist (GS-9620)
HIV cure
PHASE 1
-
Elipovimab bNAb (GS-9722)
HIV cure
PHASE 1
-
Unboosted protease inhibitor (GS-1156)
HIV treatment
PHASE 1
HBV
-
Selgantolimod TLR-8 agonist (GS-9688)
HBV cure
PHASE 2
-
PD-L1 inhibitor (GS-4224)
HBV cure
PHASE 1
1 European Commission Conditional Marketing Approval and US Emergency Use Authorization granted.
2 Phase 2 study conducted in treatment naïve patients to support virologically suppressed indication.
3 Phase 2 studies are academic collaborations.
HTE – heavily treatment-experienced.
Inflammatory Diseases
-
Filgotinib JAK-1 inhibitor (GS-6034)
Rheumatoid arthritis
FILED NDA/MAA
-
Filgotinib JAK-1 inhibitor (GS-6034)
Ulcerative colitis
PHASE 3
-
Filgotinib JAK-1 inhibitor (GS-6034)
Crohn's disease
PHASE 3
-
Filgotinib JAK-1 inhibitor (GS-6034)
Psoriatic arthritis
PHASE 3
-
Filgotinib JAK-1 inhibitor (GS-6034)
Ankylosing spondylitis
PHASE 2
-
Filgotinib JAK-1 inhibitor (GS-6034)
Uveitis
PHASE 2
-
TPL2 inhibitor (GS-4875)
Ulcerative colitis
PHASE 2
-
ADAMTS-5 Inhibitor (GLPG-1972)1
Osteoarthritis
PHASE 2
-
IRAK4 inhibitor (GS-5718)
IBD
PHASE 1
-
GLPG-33121
Inflammatory diseases
PHASE 1
-
GLPG-39701
Inflammatory diseases
PHASE 1
-
GLPG-36671
Inflammatory diseases
PHASE 1
-
GLPG-31211
Inflammatory diseases
PHASE 1
-
GLPG-05551
Osteoarthritis
PHASE 1
Fibrotic Diseases
-
Cilofexor FXR agonist (GS-9674)
PSC
PHASE 3
-
Ziritaxestat ATX inhibitor (GLPG-1690)2
Idiopathic pulmonary fibrosis
PHASE 3
-
Cilofexor, firsocostat combination3
NASH
PHASE 2
-
Selonsertib ASK1 inhibitor (GS-4997)
DKD
PHASE 2
-
Ziritaxestat ATX inhibitor (GLPG-1690)2
Systemic sclerosis
PHASE 2
-
GLPG-12051
Idiopathic pulmonary fibrosis
PHASE 2
1 Optionable partner program.
2 Optioned partner program.
3 Combination of cilofexor FXR agonist and firsocostat ACC inhibitor (selonsertib no longer included).
Oncology
Cell Therapy
-
Axi-cel
2L DLBCL
PHASE 3
-
Axi-cel
Indolent NHL
PHASE 2 Pivotal
-
Axi-cel
1L DLBCL
PHASE 2
-
Axi-cel
3L DLBCL (+rituximab)
PHASE 2
-
Brexu-cel
Adult ALL
PHASE 2 Pivotal
-
Brexu-cel
Pediatric ALL
PHASE 2 Pivotal
-
Axi-cel
3L DLBCL (+mavrilimumab)
PHASE 2
-
Axi-cel
3L DLBCL (+lenzilumab)
PHASE 2
-
Brexu-cel
CLL
PHASE 1
-
Axi-cel
3L DLBCL (+utomilumab)
PHASE 1
-
KITE-718 (MAGE-A3/A6)
Solid tumor
PHASE 1
-
KITE-439 (HPV-16 E7)
Solid tumor
PHASE 1
Non-Cell Therapy
-
Arcus – TIGIT1
ONC
PHASE 2
-
Arcus – Adenosine Antagonist1
ONC
PHASE 2
-
Arcus – PD12
ONC
PHASE 1
-
Magrolimab (GS-4721)
MDS
PHASE 3
-
Magrolimab (GS-4721)
AML
PHASE 1
-
Magrolimab (GS-4721)
NHL
PHASE 1
-
Arcus – CD73 SM1
ONC
PHASE 1
-
Oral PD-L1 SM (GS-4224)
NSCLC
PHASE 1
-
Anti-CD73/TGFß TRAP (GS-1423)1
Solid tumor
PHASE 1
-
Bi-specific mAb (AGEN1223)1
Multiple
PHASE 1
-
Anti-CD137 mAb (AGEN2373)1
Multiple
PHASE 1
1 Optionable Partner Program.
2 In-licensed from Arcus.
3 Q1’20 representation of program phase based on criteria used by Forty Seven.
Axi-cel- Axicabtagene Ciloleucel.
Brexu-cel - brexucabtageneautoleucel, formerly KTE-X19.
ALL - Acute lymphocytic leukemia.
CLL - Chronic lymphocytic leukemia.
DLBCL - Diffuse large B-cell lymphoma.
iNHL - Indolent non-Hodgkin lymphoma.
MCL - Mantle cell lymphoma.
Some of the content on this page is not intended for users outside the US.